Recurring mutations found by sequencing an acute myeloid leukemia genome

Elaine R. Mardis, Li Ding, David J. Dooling, David E. Larson, Michael D. McLellan, Ken Chen, Daniel C. Koboldt, Robert Fulton, Kim D. Delehaunty, Sean D. McGrath, Lucinda A. Fulton, Devin P. Locke, Vincent J. Magrini, Rachel M. Abbott, Tammi L. Vickery, Jerry S. Reed, Jody S. Robinson, Todd Wylie, Scott M. Smith, Lynn CarmichaelJames M. Eldred, Christopher C. Harris, Jason Walker, Joshua B. Peck, Feiyu Du, Adam F. Dukes, Gabriel E. Sanderson, Anthony M. Brummett, Eric Clark, Joshua F. McMichael, Rick J. Meyer, Jonathan K. Schindler, Craig S. Pohl, John W. Wallis, Xiaoqi Shi, Ling Lin, Heather Schmidt, Yuzhu Tang, Carrie Haipek, Madeline E. Wiechert, Jolynda V. Ivy, Joelle Kalicki, Glendoria Elliott, Rhonda E. Ries, Jacqueline Payton, Peter Westervelt, Michael H. Tomasson, Mark Watson, Jack Baty, Sharon Heath, William D. Shannon, Rakesh Nagarajan, Daniel Link, Matthew Walter, Timothy A. Graubert, John Dipersio, Richard K. Wilson, Timothy Ley

Research output: Contribution to journalArticle

1574 Scopus citations

Abstract

BACKGROUND: The full complement of DNA mutations that are responsible for the pathogenesis of acute myeloid leukemia (AML) is not yet known. METHODS: We used massively parallel DNA sequencing to obtain a very high level of coverage (approximately 98%) of a primary, cytogenetically normal, de novo genome for AML with minimal maturation (AML-M1) and a matched normal skin genome. RESULTS: We identified 12 acquired (somatic) mutations within the coding sequences of genes and 52 somatic point mutations in conserved or regulatory portions of the genome. All mutations appeared to be heterozygous and present in nearly all cells in the tumor sample. Four of the 64 mutations occurred in at least 1 additional AML sample in 188 samples that were tested. Mutations in NRAS and NPM1 had been identified previously in patients with AML, but two other mutations had not been identified. One of these mutations, in the IDH1 gene, was present in 15 of 187 additional AML genomes tested and was strongly associated with normal cytogenetic status; it was present in 13 of 80 cytogenetically normal samples (16%). The other was a nongenic mutation in a genomic region with regulatory potential and conservation in higher mammals; we detected it in one additional AML tumor. The AML genome that we sequenced contains approximately 750 point mutations, of which only a small fraction are likely to be relevant to pathogenesis. CONCLUSIONS: By comparing the sequences of tumor and skin genomes of a patient with AML-M1, we have identified recurring mutations that may be relevant for pathogenesis.

Original languageEnglish
Pages (from-to)1058-1066
Number of pages9
JournalNew England Journal of Medicine
Volume361
Issue number11
DOIs
StatePublished - Sep 10 2009

Fingerprint Dive into the research topics of 'Recurring mutations found by sequencing an acute myeloid leukemia genome'. Together they form a unique fingerprint.

  • Cite this

    Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R., Delehaunty, K. D., McGrath, S. D., Fulton, L. A., Locke, D. P., Magrini, V. J., Abbott, R. M., Vickery, T. L., Reed, J. S., Robinson, J. S., Wylie, T., Smith, S. M., ... Ley, T. (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. New England Journal of Medicine, 361(11), 1058-1066. https://doi.org/10.1056/NEJMoa0903840